Jefferies Group LLC restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Thursday morning, MarketBeat.com reports. Jefferies Group LLC currently has a GBX 5,100 ($67.08) price objective on the biopharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on AZN. Investec increased their price target on AstraZeneca plc from GBX 4,900 ($64.45) to GBX 5,500 ($72.34) and gave the stock a buy rating in a research report on Monday, November 6th. J P Morgan Chase & Co set a GBX 4,200 ($55.24) price target on AstraZeneca plc and gave the stock a neutral rating in a research report on Wednesday, August 9th. Barclays PLC reissued an overweight rating and set a GBX 5,500 ($72.34) price target on shares of AstraZeneca plc in a research report on Monday, August 7th. HSBC Holdings PLC raised their price objective on AstraZeneca plc from GBX 4,340 ($57.08) to GBX 4,380 ($57.61) and gave the company a reduce rating in a research report on Thursday. Finally, UBS AG set a GBX 4,550 ($59.84) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of GBX 5,150.82 ($67.75).
AstraZeneca plc (LON:AZN) opened at GBX 4,957 ($65.20) on Thursday. AstraZeneca plc has a 52-week low of GBX 49.50 ($0.65) and a 52-week high of GBX 5,520 ($72.60).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.